Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8629129 | MILLICENT | Pharmaceutical compositions |
Aug, 2028
(4 years from now) | |
US8957054 | MILLICENT | Pharmaceutical compositions |
Jan, 2030
(6 years from now) | |
US8268806 | MILLICENT | Pharmaceutical compositions |
Mar, 2031
(7 years from now) |
Intrarosa is owned by Millicent.
Intrarosa contains Prasterone.
Intrarosa has a total of 3 drug patents out of which 0 drug patents have expired.
Intrarosa was authorised for market use on 16 November, 2016.
Intrarosa is available in insert;vaginal dosage forms.
Intrarosa can be used as intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
The generics of Intrarosa are possible to be released after 19 March, 2031.
Drugs and Companies using PRASTERONE ingredient
Market Authorisation Date: 16 November, 2016
Treatment: Intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause
Dosage: INSERT;VAGINAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic